

For more information about FILSPARI®, please visit FILSPARIhcp.com and for additional information regarding REMS, visit FILSPARI-REMS.com.

*INDICATES REQUIRED FIELD

PATIENT INFORMATION

Name*: (First) _____ (MI) _____ (Last) _____
 Date of Birth*: ____/____/_____
 Mobile Phone*: (____) _____-____ Home Phone: (____) _____-____
 Sex Assigned at Birth: Male Female
 Shipping Address*: _____ Apt #: _____
 City*: _____ State*: _____ ZIP Code*: _____
 Email*: _____
 Preferred language: English Spanish Other: _____
 Preferred method of contact: Phone Email Text

PATIENT INSURANCE INFORMATION

FILL OUT INFORMATION OR ATTACH COPIES OF FRONT AND BACK OF PRESCRIPTION INSURANCE CARDS

Prescription Drug Insurance Patient does not have insurance
 Primary pharmacy carrier*: _____
 Policy Phone*: (____) _____-_____
 Name of insured (Cardholder)*: _____
 Rx Member ID*: _____ Rx Group ID: _____
 Rx BIN: _____ Rx PCN: _____

PATIENT CERTIFICATION AND AUTHORIZATION

By signing below, I confirm that I have read and understand the Authorization to Share Health Information and Patient Support on page 2 and agree to the terms.

Signature of Patient or Legal Representative*: _____ Date*: ____/____/_____

Printed Name of Patient or Legal Representative: _____
 Relationship to Patient (if applicable): _____

I would like to opt in for other programs and resources from Traverre and its service providers and agree to the Opt-In for Other Resources terms on page 2 (optional).

PRESCRIBER INFORMATION

Full Prescriber Name*: _____
 Prescriber NPI*: _____
 Name of Office*: _____
 Prescriber Specialty: _____
 Address*: _____
 City*: _____ State*: _____ ZIP Code*: _____
 Contact Name*: _____
 Office Contact Email: _____
 Phone*: (____) _____-____ Office Fax*: (____) _____-____
 Office Contact Phone (if different): (____) _____-____ ext: _____

CLINICAL INFORMATION *ALL INFORMATION IN THIS SECTION REQUIRED TO PREVENT DELAY IN PROCESSING

Diagnosis*: Primary Immunoglobulin A Nephropathy (IgAN)
 Other: _____
 Has the patient had a kidney biopsy*? Yes No
 Patient proteinuria level: _____ g/g g/day other units _____
 ICD-10 Code(s)*: N02.B._____
(Recurrent and Persistent Immunoglobulin A Nephropathy) Other _____
(Specify ICD Code)
 eGFR: ____ mL/min/1.73m² Previous medication: _____
 Concurrent medications: _____
 The patient will discontinue ACEis/ARBs prior to starting FILSPARI Yes No Allergies _____
 NKDA
 Please attach IgAN applicable clinical notes

PRESCRIPTION FILSPARI® (sparsentan) prescription includes both the initiation and maintenance

Initiation Rx (30 days of therapy) Quantity: 46 tablets
Days 1-14: Take one 200 mg tablet PO QD
Days 15-30: Take two 200 mg tablets PO QD
 Refills: 0

Maintenance Rx (30 days of therapy) Quantity: 30 tablets
 Recommended: **400 mg** one tablet PO QD x 30 days _____ refills
 Other: 200 mg one tablet PO QD x 30 days _____ refills

QuickStart PRESCRIPTION

By selecting QuickStart I believe my patient is at risk of rapid disease progression and a delay in therapy could lead to a negative outcome. I authorize TC Script to provide up to 60 days' supply of FILSPARI® dispensed directly to the above-named patient at no cost.

This prescription includes both the initiation and maintenance doses.
QuickStart Initiation Rx (30 days of therapy)
 Days 1-14: FILSPARI® (sparsentan) Take one 200 mg tablet PO QD
 Days 15-30: FILSPARI® (sparsentan) Take two 200 mg tablets PO QD
 Refills: 0 Quantity: 46 tablets
QuickStart Maintenance Rx (pending payer decision, additional 30 day supply available, if needed)
 FILSPARI® (sparsentan) Take one 400 mg tablet PO QD **Refills: 0 Quantity: 30 tablets**
 Other: 200 mg tablet PO QD **Refills: 0 Quantity: 30 tablets**

PRESCRIBER AUTHORIZATION

The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Prescriber Signature (dispense as written) _____ Date of Signature (mm/dd/yyyy) ____/____/_____

Prescriber Signature (substitution permitted) _____ Date of Signature (mm/dd/yyyy) ____/____/_____

By signing above, I verify that my patient has provided a signed HIPAA Authorization that allows me to share protected health information with Traverre TotalCare® for purposes of the Patient Support Program. I further verify the information and prescription provided in this FILSPARI® Start Form and Prescription is complete and accurate to the best of my knowledge. I certify that this medication is medically necessary for the patient. I understand that Traverre Therapeutics, Inc. ("Traverre") reserves the right at any time and for any reason, without notice, to modify this form or to modify or discontinue any services or assistance provided through Traverre TotalCare®. I authorize Traverre and its designated agents to use and discontinue any services or assistance provided through Traverre TotalCare®. I authorize Traverre and its designated agents to use and disclose health information as necessary to verify the accuracy of any information provided, to provide reimbursement services through Traverre TotalCare®, (as applicable) to assess my patient's eligibility for copay assistance and for quality and data assurance purposes.

By signing this form, I further certify that the information provided in this form is accurate to the best of my knowledge and that the patient meets the eligibility requirements of any Traverre TotalCare® selected above, including without limitation, the requirement that the patient be prescribed FILSPARI for an FDA-approved indication. I acknowledge and agree that I may not bill for medication dispensed under the QuickStart Program or Patient Assistance Program to any private or government payer or other third party and that I will adhere to the terms and conditions of the programs.

I authorize Traverre or its affiliated companies or subcontractors, including in-network specialty pharmacies, through Traverre TotalCare® to forward this prescription electronically, by facsimile, or by mail to the relevant in-network pharmacy for the above-named patient. I also authorize Traverre TotalCare® to perform any steps necessary to obtain reimbursement for FILSPARI, including but not limited to insurance verification and case assessment.

Authorization to Share Health Information and Patient Support

The Traverre TotalCare® Program (“Program”) is a support program for patients by Traverre Therapeutics, Inc. (“Traverre”). Before signing, the patient and/or patient’s authorized representative should review and understand the terms of this Authorization to Share Health Information and Patient Support (“Authorization”). *If an authorized representative signs for the patient, please indicate the relationship to the patient.*

I understand that the collection, use, and disclosure of the patient’s health information are protected under law. Information contained in this FILSPARI® Start Form and Prescription, such as the patient’s name, address, insurance, prescription, and medical information, may be “protected health information” (“PHI”). By signing this Authorization, the patient agrees to the collection, use, and disclosure of the patient’s PHI as described below and authorizes their treating physician, healthcare provider, health insurer, or pharmacist (“Insurer and Treating Providers”) to share such information with Traverre and the company or companies that help Traverre administer the Program’s Support Services (“Services”).

I understand that once PHI about the patient is released based on this Authorization, federal privacy laws may not prevent Traverre and company or companies who administer the Services from further disclosing the patient’s information. However, I understand that such entities have agreed to use or disclose PHI they receive only for the purposes described in this Authorization or as required by law.

By signing this form, I authorize Traverre and the company or companies that help administer the Services, to do the following:

- Request and receive information from the patient’s Insurer and Treating Providers necessary to investigate and resolve the patient’s insurance coverage, coding, or reimbursement inquiry or to provide the reimbursement support service that I have requested. Information may include the patient’s medical diagnosis, condition, and treatment (including prescription information), the patient’s health insurance, name, address, and telephone number;
- Collect, use, and disclose any patient information including patient name, contact information, information related to disease, diagnosis, and treatment, medical insurance information, some of which may be considered PHI or consumer health data as defined by applicable law, for the purpose of investigating and resolving the patient’s insurance coverage, coding, or reimbursement inquiry or to administer the Services, including entering and maintaining the patient’s information in a database;
- Disclose patient information as described above with Traverre’s service providers, contractors, analytics service providers, and business partners, including our business partners who support our research, surveys, focus groups or interviews related to the patient’s diagnosis and the effectiveness of the Program;
- Disclose patient information as described above to the patient’s Insurer and Treating Providers as necessary to resolve the patient’s insurance coverage, coding, or reimbursement inquiry. The patient authorizes their Insurer and Treating Providers to release PHI about the patient’s prescribed medications and medical condition requested by Traverre and the company or companies that help Traverre administer the Services;
- Contact the patient’s plan(s) about their insurance benefit, coverage status, and product administration (e.g., prescription, dosing, refills);
- Provide financial assistance resources, including copay assistance or free drug programs if I meet program eligibility; and
- Contact the patient’s insurer, other potential funding sources, social workers, patient advocacy organizations, or patient assistance programs (e.g., the Traverre TotalCare® Program) on the patient’s behalf to determine if the patient may be eligible for health insurance coverage or other funds, and disclose to them PHI about the patient’s prescribed medications and medical condition that has been provided by the patient or patient’s authorized representative or patient’s Insurer and Treating Providers.

I understand that I may decline to sign this Authorization, and that doing so will not affect the patient’s ability to receive FILSPARI® (sparsentan) or obtain insurance or insurance coverage. This Authorization will expire in 10 years or a shorter period if required by state law. I understand that I may revoke or cancel it at any time by calling 1-833-345-7727 or by writing to Traverre TotalCare®, 2250 Perimeter Park Dr, Suite 300, Morrisville, NC 27560. I understand that I am entitled to receive a copy of this Authorization, upon request.

I further understand that revoking this Authorization will prohibit PHI disclosures after the date written revocation is received by the Program, except to the extent that action has been taken already on this Authorization. After I revoke this Authorization, the patient’s PHI may be disclosed among Traverre and the company or companies that help Traverre administer the Services in order to maintain records of the patient’s participation, but it will not be otherwise disclosed or used. Further information on Traverre’s privacy practices can be found at <https://traverre.com/privacy/>.

I understand that the pharmacy who may administer some of the Services may receive payment from Traverre as the manufacturer in exchange for securely sharing the patient’s PHI with companies who administer the Services.

Opt-In for Other Resources

By checking the box on page one, I additionally authorize Traverre and its service providers to contact me by mail, email, telephone, or alternative communication to discuss and receive marketing communications, invitations to participate in research, educational materials, treatment support services and patient engagement initiatives designed for people taking FILSPARI®, including nutritional support and counseling.

Power of Attorney documentation is required if an adult other than the patient signs. You may fax the documents to 888-381-0625 or call 833-345-7727 for further assistance. NOTE: Enrollment cannot be processed without a valid signature.



Mail us at
Traverre TotalCare®
2250 Perimeter Park Drive Suite 300
Morrisville, NC 27560



Call us at
833-345-7727
Monday-Friday, 8 AM-8 PM ET



Fax us at
888-381-0625



How to get your patients started on FILSPARI® (sparsentan)



One-time Prescriber REMS certification

A one-time Risk Evaluation and Mitigation Strategies (REMS) certification is required and must be implemented prior to prescribing FILSPARI® for your patients. You can find the REMS guide and enrollment form in your Traverre Starter Kit for FILSPARI® treatment or online at www.FILSPARI-REMS.com.



Information you will need: Patient data, including all benefit insurance information (prescription, medical, and secondary benefit insurance), recent proteinuria/UPCR and eGFR values, kidney biopsy documents, and patient medications (past and present).



Patient REMS enrollment

- Fill out all required fields in the enrollment form indicated by an asterisk(*).
- Have patient and prescriber sign and date this form. Both signatures are required.
- Fax completed form and supporting documents to **888-381-0625**.



After FILSPARI Start Form and Prescription Submission

TRAVERE TotalCare® will follow up with a call to the patient and prescriber in case there is any missing information still needed, and to welcome the patient to the program.



We are here to help



Call: 1-833-FILSPARI (833-345-7727)
Monday - Friday: 8AM-8PM ET



Fax: 888-381-0625